CN105054025B - A kind of hypotonic low slag type enteral nutrition powder of low fat for patients with inflammatory bowel disease - Google Patents
A kind of hypotonic low slag type enteral nutrition powder of low fat for patients with inflammatory bowel disease Download PDFInfo
- Publication number
- CN105054025B CN105054025B CN201510485578.5A CN201510485578A CN105054025B CN 105054025 B CN105054025 B CN 105054025B CN 201510485578 A CN201510485578 A CN 201510485578A CN 105054025 B CN105054025 B CN 105054025B
- Authority
- CN
- China
- Prior art keywords
- fat
- patients
- low
- powder
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 46
- 230000035764 nutrition Effects 0.000 title claims abstract description 43
- 239000000843 powder Substances 0.000 title claims abstract description 30
- 235000004213 low-fat Nutrition 0.000 title claims abstract description 26
- 239000002893 slag Substances 0.000 title claims abstract description 21
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 18
- 235000018102 proteins Nutrition 0.000 claims abstract description 22
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 16
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 16
- 150000004667 medium chain fatty acids Chemical class 0.000 claims abstract description 15
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 14
- 239000011707 mineral Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 229940030275 epigallocatechin gallate Drugs 0.000 claims abstract description 12
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 5
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 5
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 3
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 3
- 150000004668 long chain fatty acids Chemical class 0.000 claims abstract description 3
- 235000021119 whey protein Nutrition 0.000 claims abstract description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 14
- 239000002002 slurry Substances 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000006226 Areca catechu Nutrition 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011772 phylloquinone Substances 0.000 claims description 2
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 claims 1
- 244000080767 Areca catechu Species 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 abstract description 17
- 235000005911 diet Nutrition 0.000 abstract description 16
- 230000037213 diet Effects 0.000 abstract description 15
- 230000003204 osmotic effect Effects 0.000 abstract description 10
- 230000007661 gastrointestinal function Effects 0.000 abstract description 8
- 230000000968 intestinal effect Effects 0.000 abstract description 8
- 206010033645 Pancreatitis Diseases 0.000 abstract description 7
- 206010019280 Heart failures Diseases 0.000 abstract description 6
- 230000002496 gastric effect Effects 0.000 abstract description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 230000007704 transition Effects 0.000 abstract description 5
- 238000001356 surgical procedure Methods 0.000 abstract description 4
- 238000002192 cholecystectomy Methods 0.000 abstract description 3
- 201000001352 cholecystitis Diseases 0.000 abstract description 3
- 208000001130 gallstones Diseases 0.000 abstract description 3
- 235000008935 nutritious Nutrition 0.000 abstract description 3
- 235000019197 fats Nutrition 0.000 description 21
- 239000002253 acid Substances 0.000 description 20
- 125000001931 aliphatic group Chemical group 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 206010000060 Abdominal distension Diseases 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 102000004407 Lactalbumin Human genes 0.000 description 6
- 108090000942 Lactalbumin Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 235000004626 essential fatty acids Nutrition 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 4
- 206010070545 Bacterial translocation Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000007375 bacterial translocation Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- -1 flavone compound Chemical class 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 101001000747 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 2A Proteins 0.000 description 2
- 101001000734 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 2B Proteins 0.000 description 2
- 208000034657 Convalescence Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- 208000034767 Hypoproteinaemia Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- NCYSTSFUYSFMEO-OBLTVXDOSA-N PGI3 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C\C=C/CC)[C@H](O)C[C@@H]21 NCYSTSFUYSFMEO-OBLTVXDOSA-N 0.000 description 2
- 206010033647 Pancreatitis acute Diseases 0.000 description 2
- 206010039163 Right ventricular failure Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- NMZKLLJQNNTBRJ-OIXZZONUSA-N TXA3 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)C\C=C/CC)O[C@@H]2O[C@H]1C2 NMZKLLJQNNTBRJ-OIXZZONUSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 201000003229 acute pancreatitis Diseases 0.000 description 2
- 210000003486 adipose tissue brown Anatomy 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 235000008452 baby food Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000235603 Acacia catechu Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010065611 Intestinal congestion Diseases 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010041954 Starvation Diseases 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The hypotonic low slag type enteral nutrition powder of low fat for patients with inflammatory bowel disease, contains following composition：Protein, fat, carbohydrate, B B-complex, mineral matter, Epigallo-catechin gallate (EGCG), and seitan is free of, protein is provided by whey protein powder, L glutamine；Fat is provided in the form of long chain fatty acids and medium chain fatty acid, ω 9=40%/40%/10%/10% of 6/ medium chain fatty acids of ω/ω 3/；Carbohydrate is maltodextrin.The suitable gastrointestinal function of the present invention is poor, easy generation diarrhoea person, or need the crowd of low fat minimal residue diet, it is initial after the just transition of oral diet, patients with heart failure, the fasting of such as patients with inflammatory bowel disease, Pancreatitis Patients to use patient after the patient of enteral nutrition, cholecystitis, gall stone, cholecystectomy, obese people, intestinal surgery preparation, gastrointestinal procedures, and provide the pulvis product of balanced nutritious support, easily reconstitute and preserve, facilitate the control of dosage and osmotic pressure, improve patients ' life quality.
Description
Technical field
The present invention relates to a kind of enteral nutrition powder, and in particular to a kind of low fat for patients with inflammatory bowel disease is hypotonic low
Slag type enteral nutrition powder, at the same suitable for gastrointestinal function it is poor, easy diarrhoea occur and need the crowd of low fat minimal residue diet.
Background technology
Enteral nutrition (EN) supports that it is the master of clinical nutrition development with fully functional to help to maintain intestinal mucosa cells structure
Want direction.When patient needs nutritional support, and has complete or part gastrointestinal function, enteral nutrition (EN) support is
Preferred approach.
IBD (inflammatory bowel disease, IBD) refers to the not clear enteron aisle chronic inflammation of reason
Property disease, mainly including Crohn disease (Crohn ' s disease, CD) and ulcerative colitis (ulcerative colitis,
UC).IBD easily causes malnutrition, Hypoproteinemia, anaemia etc..The principle of nutrition treatment is by a variety of nutrition
Support pattern, meet the nutritional need of patient, while intestines caused by inflammation are stimulated and are reduced to minimum.Paracmasis should give limitation
Property low fat minimal residue diet, fat can use Medium chain fatty.
Acute pancreatitis (acute pancreatitis, AP) refers to pancreas digestive ferment and is activated and to itself and surrounding organ
Produce diseases associated with inflammation caused by digestion.Clinically, the course of disease of Most patients is in self limiting, 20%~30% patient
Clinic is by dangerous.Overall case fatality rate is 5%~10%.Either light-duty or Severe Pancreatitis, in Nasal cavity intestinal tube nutrition treatment
Later stage and oral feeding initial stage, be required to the transition of the hypotonic low slag type enteral nutrition of low fat, with reduce to exocrine pancreas
Stimulation, make enteron aisle have one gradually adapt to and recover process.
Heart failure abbreviation heart failure, can be divided into left heart failure and right heart failure.Right heart failure is mainly that right ventricle puts out work(
Energy obstacle, now cardiac output reduction, congestion of systemic circulation, vein pressure increase, are often accompanied by edema of lower extremity, whole body can occur when serious
Property oedema.Patient may occur in which long-term gastro-intestinal congestion, show as the symptoms such as poor appetite, abdominal distension, Nausea and vomiting, indigestion,
Some even can cause stress ulcer, hemorrhage of digestive tract etc..In terms of nutrition treatment, it is also desirable to the hypotonic low slag of low fat and battalion
Support comprehensive nutrition supply.
Other：Gastrointestinal function is poor, the easy patient to suffer from diarrhoea and other need the crowd of low fat minimal residue diet, such as prohibit
Initially using the patient of enteral nutrition, cholecystitis, gall stone, cholecystectomy, intestinal surgery preparation, gastrointestinal procedures future trouble after food
Person, the patient for needing low-cholesterol diet etc., these situations are clinically relatively common, are also easy to secondary malnutrition, and one
As be required for following the nutrition treatment principle of the hypotonic low slag of low fat.
At present, the serial enteral nutrition preparation such as in the market existing " peace element ", " Nutrison Fibre ", " auspicious can ", its fat ratio compared with
Height, suitable for gastrointestinal function preferably or the relatively normal patient of fat metabolism；The serial enteral battalion such as " homogenate diet ", " Quan Yingsu "
Foster preparation contains dietary fiber, is not suitable for needing the patient of minimal residue diet；" hundred general power " although being the low slag formula of low fat, because
Its osmotic pressure is higher, and some patient's gastrointestinal tract tolerances are poor, the discomforts such as abdominal distension, diarrhoea easily occur.We are for needing simultaneously
Meet the patient of the hypotonic low slag nutrition and metabolism demand of low fat, carry out constituent and proportioning regulation, develop personalized enteral
Nutritional preparation, balanced nutritious, raising patients ' life quality is provided for associated patient.
The content of the invention
The invention provides a kind of hypotonic low slag type enteral nutrition powder of low fat for patients with inflammatory bowel disease, Ke Yirang
Intestines and stomach convalescence is easier to be resistant to, and prevention abdominal distension and diarrhoea aggravate, and provide the pulvis product of balanced nutritious support, easily punching
Reconcile and preserve, facilitate the control of dosage and osmotic pressure, improve patients ' life quality, to meet that gastrointestinal function is poor, easy generation
Diarrhoea person, or need the demand of low fat minimal residue diet crowd.
Gastrointestinal function chump, easy generation diarrhoea person and the patient for needing low fat minimal residue diet that the present invention is directed to, such as
Initially using the patient of enteral nutrition, cholecystitis, gall stone, cholecystectomy, obese people, patients with heart failure, pancreas after fasting
The scorching patient just transition of oral diet, patients with inflammatory bowel disease, intestinal surgery prepare, patient after gastrointestinal procedures, needs low cholesterol
Patient of diet etc..
A kind of hypotonic low slag type enteral nutrition powder of low fat for patients with inflammatory bowel disease, including B B-complex, ore deposit
Material, it is characterised in that the nutrition powder is by protein, fat, carbohydrate, Epigallo-catechin gallate (EGCG)
(Epigallocatechin gallate, EGCG) and described B B-complex, mineral matter form, and are free of seitan；The battalion
Support pulvis and include protein 15~17g, fatty 3.7g~4.7g, carbohydrate 76g~78g, epi-nutgall catechu per 100g
Plain gallate 40mg, remaining is B B-complex and mineral matter；Wherein described protein includes 5-7g Glu,
Other is whey protein powder.
The fat is made up of long chain fatty acids and medium chain fatty acid, and carbohydrate is made up of maltodextrin.
Described fat is made up of ω -6, medium chain fatty acid, ω -3, ω -9, and ω -6/ medium chain fatty acids/ω -3/ ω -9
=40%/40%/10%/10%.
Described vitamin includes following component：Vitamin A, vitamin D, vitamin E, vitamin K1, vitamin C, leaf
Acid, vitamin B1, vitamin B2, vitamin B6, vitamin B12, nicotinic acid, pantothenic acid, biotin, choline.Described mineral matter includes
Following component：Sodium, potassium, calcium, zinc, iron, magnesium, copper, manganese, phosphorus, iodine, selenium.
The content of B B-complex, mineral matter can be determined according to Chinese residents meals recommended intake, to meet nutrition
Needs.
The concrete component of the present invention see the table below：The active ingredient that the enteral nutrition preparation described in per 100g of table 1 contains
Compared with prior art, this product includes six big nutrients of needed by human body, and albumen is fatty, carbohydrate, simultaneously
Uniqueness with the addition of flavone compound-Epigallo-catechin gallate (EGCG).Because the state of an illness needs especially to avoid the seventh-largest battalion
Plain dietary fiber is supported, while is rich in glutamine and medium chain fatty acid, is more beneficial for the tolerance and recovery of enteron aisle, nutrition is comprehensively equal
Weighing apparatus.
Uniqueness with the addition of Epigallo-catechin gallate (EGCG).Epigallo-catechin gallate (EGCG) is in Tea Polyphenols
Maximally effective active component, belongs to catechin, also belongs to flavone compound.With anti-oxidant, antibacterial, antiviral, anti-inflammatory, resist
Artery sclerosis, antithrombus formation, antiangiogenic, strengthen immunity and antitumor action.Antioxidation activity at least ties up life
More than 100 times of plain C, it is 25 times of vitamin E, cell and DNA can be protected from infringement；In terms of anticancer and angiocardiopathy
It act as important role.And the content of low density cholesterol in serum, extremely-low density cholesterol and triglycerides can be reduced.
With the antioxidant collective effect such as vitamin C, vitamin E, free radical is removed, strengthens antioxidation.Rich in lactalbumin and
Glutamine.Lactalbumin utilization rate highest in the albumen of numerous kinds, it is the splendid source of proteinaceous nutrient supplement.Simultaneously
Immunoglobulin and lactoferrin have immunocompetence and anti-oxidation characteristics in lactalbumin, can improve immunity of organisms.Paddy ammonia
Acid amides can promote positive nitrogen equilibrium, keep intestinal mucosa complete, prevent bacterial translocation and enterotoxin from entering blood.
Fatty energy supply ratio is 8.2%-10.3%, and ratio is low；And 40% is medium chain fatty acid, can quickly be inhaled by human body
Receive, lose weight with reduction cholesterol, preventing and treating hyperlipidemia, help and other effects.Add omega-fatty acid (for essential fatty acid), tool
There are vasodilator, platelet aggregation-against and anti thrombotic action.ω -6 aliphatic acid (for essential fatty acid) is added, there is expansion blood vessel
Effect, can also stimulate brown adipose tissue, play prevent obesity effect.ω -9 aliphatic acid is added, has and improves HDL (height
Density lipoprotein), LDL (low-density lipoprotein) effect is removed, atherosclerosis can be effectively prevented and treated and cardiac muscle obstructs
Extremely, and with suppression " oncogene " effect well.
Carbohydrate is maltodextrin, and low with sugariness, free from extraneous odour is easy to digest, the characteristics such as dissolubility is good, easily by human body
Absorb, suitably make the basic material of patient and infant food, available for diabetic.
The present invention is free of seitan for low slag formula, reduces the mechanical irritation to enteron aisle, reduces intestinal tympanites and diarrhoea occurs
Rate, be extremely suitable for needing alimentary tract rest, function of intestinal canal recover during patient, such as gastrointestinal function chump, easily occur diarrhoea person,
After fasting initially using the just transition of oral diet of enteral nutrition person, patients with inflammatory bowel disease, Pancreatitis Patients, patients with heart failure,
Intestinal surgery prepares patient, the patient etc. such as after gastrointestinal procedures.
The present invention is hypotonic formula, and osmotic pressure is less than 300mmol/L H2O, it is not easy to causes abdominal distension, diarrhoea and other intestines
Road reacts, and Intestinal Mucosal Injury in Patients Undergoing tolerance is more preferable.Forced for vitamins and mineral matter addition of the present invention, can take the photograph according to China's resident's nutrient
Enter guidelines addition multivitamin and mineral matter, a variety of diseases caused by vitamin and mineral lacks can be prevented and treated.This
Invent as powder-type enteral nutrition preparation, be easy to preserve, be easily adjusted the amount reconstituted and osmotic pressure, using flexible is orally available, can
Pass through alimentary canal tube feed.
Embodiment
A kind of hypotonic low slag type enteral nutrition powder production technology of low fat for patients with inflammatory bowel disease：
1) in first blending tank, 80-100g 50- is added according to every ratio for preparing 100 grams of nutrition powders
70 DEG C of pure water, the protein of the ratio, Glu are added, and add water soluble antioxidant, 1000-
1200rpm stirs 3-5 minutes, until fully dissolving, switchs to 80-150rpm stirring at low speed, is incubated 50-70 DEG C, it is standby to obtain slurry 1
With the holding time is no more than 2 hours；
2) in second blending tank, the fat of the ratio is added, is heated to 40-60 DEG C, stirred under 300-350rpm
Mixing is mixed, and adds oil-soluble inhibitor, after abundant dissolving, obtains that slurry 2 is standby, and the holding time is no more than 2 hours；
3) in the 3rd blending tank, 80-100g 50-70 DEG C of pure water is added, adds the ratio carbohydrate,
200-300rpm stirring 5-10 minutes, it was standby to obtain slurry 3 until fully dissolving, and the holding time is no more than 12 hours；
4) step 1 is obtained into slurry 1 in 800-1200rpm high-speed stirreds, and adds slurry 2,50-70 DEG C of insulation, at least 5
Slurry 3 is added after minute, then adds pure water, regulation total solid obtains emulsion to 30-40%；
5) emulsion for obtaining step 4 crosses 100-120 mesh sieves, and 50-70 DEG C of filtrate, 25-35MPa is high-pressure homogeneous twice,
Obtain uniform and stable emulsion；
6) emulsion for obtaining step 5 is spray-dried, 160-180 DEG C of spray drying EAT, temperature of outgoing air
75-85 DEG C, obtain powder；
7) powder-product for obtaining step 6 is cooled fast to room temperature, and the epigallocatechin for being mixed into above-mentioned deal does not have
Infanticide acid esters powder, B B-complex and mineral matter powder, then vacuum or nitrogen charging individual packets dress are distributed into, it is hypotonic to finally give low fat
Low slag nutrient powder.
The protein ratio 14.8% of this embodiment of embodiment 1, fat ratio 8.2%, carbohydrate proportion 77%,
Its fat ratio is low, and carbohydrate proportion is high, the patient for the initial oral diet of more serious patient or pancreatitis that is more suitable for suffering from diarrhoea.
The protein ratio 15.6% of this embodiment of embodiment 2, fat ratio 10.3%, carbohydrate proportion 74%,
Its fat ratio is slightly higher, and carbohydrate and protein ratio are moderate, is more suitable for diarrhoea improvement patient or pancreatitis is orally drunk
Eclipse number day has no adverse reaction, and needs the patient of further transition.
Patient Lee of clinical case 1, man, 28 years old, ulcerative colitis 12 years.This is because suffering from abdominal pain, suffering from diarrhoea, pus and blood stool 7 days
It is admitted to hospital.Patient's diarrhoea more than ten times daily, are pus and blood stool, flora imbalance of defecating, seralbumin 28g/L.Gastroenterology dept. after being admitted to hospital
Give supportive treatment to the ill.
In nutrition treatment, first orally administration short peptide type enteral nutrition preparation, because osmotic pressure is higher, patient, which suffers from diarrhoea, to aggravate；Again
Give low fat hypotonic type enteral nutrition preparation treatment, because containing dietary fiber, patient's diarrhoea number is still more；After give embodiment
Formula pulvis in 1.This formula fat ratio is low, and containing Medium chain fatty, osmotic pressure is relatively low and without slag, the disease of this suitable patient
Feelings.Orally rear well-tolerated, times of defecation gradually decrease patient, and albumin gradually gos up.After one week, times of defecation is reduced
To be daily 5-6 times, seralbumin rises to 30g/L.
Conditions of patients improves earlier above, gradually replaces with the formula pulvis in embodiment 2.The ratio of this formula fat and protein
Example is above embodiment 1, is adapted to the patient of ulcerative colitis convalescence.Using rear patient's state of an illness not repeatedly, and further by
Gradually recover.After another week, times of defecation is reduced to daily 3-4 times, and seralbumin recovers to 33g/L.Nutrition treatment effect compared with
It is preferable.
The protein ratio 16.8% of this embodiment of embodiment 3, fat ratio 8.2%, carbohydrate proportion 75%,
Its fat ratio is low, and protein ratio is slightly higher, is more suitable for needing low fat minimal residue diet and the low patient of haemocyanin.
The patient Zhang of clinical case 1, female, 59 years old, chronic right-sided heart failure.Poor appetite, nausea, abdominal distension, double lower limb water
It is swollen.Patient usually feeds bad, protein hypoalimentation, more serious Hypoproteinemia, seralbumin 26g/L occurs.
In nutrition treatment, normal fat ratio nutrient formulation powder is given, patient's abdominal distension aggravates.Give the battalion in embodiment 3
Formula powder is supported, this formula fat ratio is low, and protein ratio is high, and infiltration is forced down and without slag, is adapted to patient's present case.Orally
Tolerance is preferable afterwards, and no nausea, abdominal distension aggravate.After three weeks, patient's albumin level rises to 30g/L, double lower limb oedema
Improve, and occur without other new unfavorable conditions.
Lactalbumin utilization rate highest in the albumen of numerous kinds.The biological value 104 of lactalbumin, protein efficiency ratio
3.2nd, net utilization 92, three groups of data are above lactoprotein (biological value 91, protein efficiency ratio 3.1, net utilization 82), junket egg
(biological value 77, protein efficiency ratio 2.5, net utilization 76) and soybean protein are (biological value 74, protein efficiency ratio 2.1, net in vain
Utilization rate 61), it is the splendid source that proteinaceous nutrient supplements.Immunoglobulin and lactoferrin have and exempted from lactalbumin simultaneously
Epidemic disease activity and anti-oxidation characteristics, can improve immunity of organisms.
Glutamine (glutamine, Gln) is free amino acid most abundant in human body, and it is total to account for Free Amino
The 20% of amount.The main energy sources of enteron aisle are Gln, and non-glucose.Enteron aisle is the most important consumption organs of Gln, and it may be used also
It is utilized as the fuel of other rapid proliferative cells (such as immunocyte).Numerous studies show that Gln can promote ortho-nitrogen to put down
Weighing apparatus, keep intestinal mucosa complete, prevent bacterial translocation and enterotoxin from entering blood.Gln is condition nonessential amino acid, in catabolism
During disease, it is a kind of essential amino acid.When endogenous Gln insufficient supply, make at protection of intestinal mucosal barrier cells and immunocyte
In Gln starvations, Gln is such as supplemented by the external world not in time, then muscle consumption accelerates, protection of intestinal mucosal barrier cells metabolism substrate deficiency, intestines
Mucosa Barrier is destroyed, and bacterial translocation from intestine occurs.
Omega-fatty acid is the essential fatty acid that human body itself can not be synthesized, must absorbed from food, and composition is main
There are three kinds：Alpha-linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA).Omega-fatty acid participates in arachidonic
Sour (Eicosatetraeonic acid) metabolism, generation prostanoid PGI3 and TXA3.Arachidonic metabolism
Thing is prostacyclin (PGI2) and thromboxane (TXA2)；PGI2 can vasodilator and platelet aggregation-against, prevent thrombosis；
TXA2 can then make vasopasm, promote platelet aggregation and thrombosis.PGI3 effect is identical with PGI2；But TXA3 does not have
TXA2 effect.Therefore omega-fatty acid has vasodilator, platelet aggregation-against and anti thrombotic action.
ω -6 aliphatic acid is polybasic unsaturated fatty acid, belongs to essential fatty acid, can not voluntarily be synthesized in human body, it is necessary to
Obtained from food.ω -6 aliphatic acid can change into arachidonic acid in human body, can kill tumour cell, and to normal thin
Born of the same parents have no toxic side effect, and have the function that to expand blood vessel, can stimulate brown adipose tissue, play the effect for preventing obesity.In pharmacopeia
Using ethyl linoleate as the medicine for preventing and treating hypertension, atherosclerosis, coronary heart disease.But some medical science are ground
Study carefully and show, excessive ω -6 aliphatic acid can disturb benefit of the omega-fatty acid to health, because they can fight for identical speed limit
Enzyme.ω -6 aliphatic acid of long-term excess can cause chronic cardiac onste, embolic stroke, cardiac arrhythmia, arthritis, sclerotin to be dredged
The diseases such as loose disease, inflammation, emotional handicap, fat and cancer.Too high ω -6 aliphatic acid：Omega-fatty acid ratio, displaced group
The physiological status to many disease incidence mechanism, such as thrombus, inflammation etc. are knitted, the probability of some diseases may be increased.Therefore,
It is now recognized that ω -6 aliphatic acid：The optimal proportion of omega-fatty acid is 4：1 or lower.
ω -9 aliphatic acid is monounsaturated fatty acids, is obtained afterwards because its first double bond appears in the 9th carbon atom
Name.It can be synthesized in vivo, therefore be non-essential fatty acid.ω -9 aliphatic acid is safety coefficient highest aliphatic acid.First, it
Molecular structure stabilized, so as to have extremely strong oxidation resistance, its AOM value (the stability standard of comparison of oxidation) is up to 80, takes the photograph
Entering excessive will not also be oxidized to can be with the DNA in damaging cells so as to causing lipid peroxide caused by malignant tumour.Secondly,
ω -9 aliphatic acid can improve HDL (HDL), remove LDL (low-density lipoprotein), can effectively prevent and treat artery
Atherosis and myocardial infarction.In addition, ω -9 aliphatic acid also has suppresses " oncogene " effect well.ω -9 content of fatty acid
Highest grease is olive oil, thus olive oil is described as " long life oil ", " liquid golden " again.In addition, tea oil, rapeseed oil, flower
Oil generation, sesame oil etc. are all containing abundant ω -9 aliphatic acid.
Medium chain fatty acid (medium chain fatty acid, MCFA) is usually to form carbon containing 6~12 carbon atoms
The aliphatic acid of chain, it is the aliphatic acid that comparision contents are few in nature, is mainly derived from breast milk, milk and its product, palm-kernel oil
With coconut oil etc., representational MCFA has octanoic acid and capric acid.Medium chain fatty acid in daily ingestion food is often with medium chain triglyceride three
The form of ester (MCT) is present.Typical MCT refer to saturation Trivent OCG or saturation Triglyceride DDD or saturation octanoic acid-
The triglycerides of capric acid mixing.
Medium chain triglyceride (MCT) is only made up of saturated fatty acid, and freezing point is low, is at room temperature liquid, viscosity is small.With it is big
Soya-bean oil compares, and is entirely odorless, colourless transparency liquid.Compared with common grease and hydrogenated oil and fat, in medium chain triglyceride
The content of unrighted acid is extremely low, and oxidation stability is very good, and its iodine number is no more than 0.5.Therefore MCT is special under high temperature and low temperature
Wen Ding not.Medium chain triglyceride has good dissolubility and can be rapidly absorbed, and its molecular weight is small, and hydrolysis rate compares long-chain
Triglycerides (LCT) soon, and is not required to camitine transporter, is directly decomposed by portal vein to liver and produces energy, it is digested and assimilated
Speed is 4 times of LCT, and accretion rate is 10 times of LCT.It has been proved in the 1950s to malabsorption syndrome
Dietary therapy has clinical value, is normally used as the special food of Post operation, infection and skin burn patient, it may also be used for that
A bit with fat absorption is bad, aids patient and cancer patient, the food of diabetes patient, and for treat hyperplasia of prostate,
Dissipation cholelith, reduce cholesterol, anti-curing hyperlipemia etc..In addition it may also help in fat-reducing, in practice it has proved that, MCT is eaten to human body
Body weight, stomach fat area reduction, the reduction of waistline, have obvious effect.
Maltodextrin is DE values 5-20 starch hydrolysate, is that one kind is cheap, mouthfeel is satiny, without any taste
Trophism polysaccharide.It is not only that body provides energy, also low with sugariness, free from extraneous odour is easy to digest, the characteristics such as dissolubility is good, pole
Easily it is absorbed by the body, the particularly suitable basic material for making patient and infant food.And it can be used for diabetic.
Osmotic pressure is closely related with gastrointestinal toleration, compared with hyperosmosis preparation easily cause abdominal distension, diarrhoea and other
Enteron aisle reacts, and the enteral formula of the whole albumen of standard is typically isotonic, about 300mmol/L H2O.Usual whole albumen is nitrogen source
Its osmotic pressure of enteral nutrition preparation is relatively low, and the osmotic pressure of key element type enteral nutrition preparation is then higher.
Claims (4)
1. a kind of hypotonic low slag type enteral nutrition powder of low fat for patients with inflammatory bowel disease, including B B-complex, mineral
Matter, it is characterised in that the nutrition powder is by protein, fat, carbohydrate, Epigallo-catechin gallate (EGCG)
(Epigallocatechin gallate, EGCG) and described B B-complex, mineral matter composition, and be free of seitan；Should
Nutrition powder includes protein 15~17g, fatty 3.7g~4.7g, carbohydrate 76g~78g, epigallocatechin gallate per 100g
Catechin gallate 40mg, remaining is B B-complex and mineral matter；Wherein described protein includes 5-7g L- glutamy
Amine, other is whey protein powder；
The fat is made up of long chain fatty acids and medium chain fatty acid, and the carbohydrate is made up of maltodextrin.
2. it is used for the hypotonic low slag type enteral nutrition powder of low fat of patients with inflammatory bowel disease, its feature as claimed in claim 1
It is that described fat is made up of ω -6, medium chain fatty acid, ω -3, ω -9, and ω -6/ medium chain fatty acids/ω -3/ ω -9=
40%/40%/10%/10%.
3. it is used for the hypotonic low slag type enteral nutrition powder of low fat of patients with inflammatory bowel disease, its feature as claimed in claim 1
It is that described vitamin includes following component：Vitamin A, vitamin D, vitamin E, vitamin K1, vitamin C, folic acid, dimension
Raw plain B1, vitamin B2, vitamin B6, vitamin B12, nicotinic acid, pantothenic acid, biotin, choline；
Described mineral matter includes following component：Sodium, potassium, calcium, zinc, iron, magnesium, copper, manganese, phosphorus, iodine, selenium.
A kind of 4. preparation method of the hypotonic low slag type enteral nutrition powder of low fat for patients with inflammatory bowel disease, it is characterised in that
Comprise the following steps：
1) in first blending tank, 50-70 DEG C of 80-100g is added according to every ratio for preparing 100 grams of nutrition powders
Pure water, protein, the Glu of ratio described in claim 1 are added, and add water soluble antioxidant, 1000-
1200rpm stirs 3-5 minutes, until fully dissolving, switchs to 80-150rpm stirring at low speed, is incubated 50-70 DEG C, it is standby to obtain slurry 1
With the holding time is no more than 2 hours；
2) in second blending tank, the fat of ratio described in claim 1 is added, 40-60 DEG C is heated to, in 300-350rpm
Under stir and evenly mix, and add oil-soluble inhibitor, after abundant dissolving, obtain that slurry 2 is standby, and it is small that the holding time is no more than 2
When；
3) in the 3rd blending tank, 80-100g 50-70 DEG C of pure water is added, adds ratio carbon aquation described in claim 1
Compound, 200-300rpm stirring 5-10 minutes, it was standby to obtain slurry 3 until fully dissolving, and the holding time is no more than 12 hours；
4) step 1 is obtained into slurry 1 in 800-1200rpm high-speed stirreds, and adds slurry 2, be incubated 50-70 DEG C, at least 5 minutes
Slurry 3 is added afterwards, then adds pure water, and regulation total solid obtains emulsion to 30-40%；
5) emulsion for obtaining step 4 crosses 100-120 mesh sieves, and 50-70 DEG C of filtrate, 25-35MPa is high-pressure homogeneous twice, obtains
Even stable emulsion；
6) emulsion for obtaining step 5 is spray-dried, 160-180 DEG C of spray drying EAT, temperature of outgoing air 75-85
DEG C, obtain powder；
7) powder-product for obtaining step 6 is cooled fast to room temperature, is mixed into the epi-nutgall catechu of ratio described in claim 1
Plain gallate powder, B B-complex and mineral matter powder, then vacuum or nitrogen charging individual packets dress are distributed into, finally give low fat
Hypotonic low slag nutrient powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510485578.5A CN105054025B (en) | 2015-08-09 | 2015-08-09 | A kind of hypotonic low slag type enteral nutrition powder of low fat for patients with inflammatory bowel disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510485578.5A CN105054025B (en) | 2015-08-09 | 2015-08-09 | A kind of hypotonic low slag type enteral nutrition powder of low fat for patients with inflammatory bowel disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105054025A CN105054025A (en) | 2015-11-18 |
| CN105054025B true CN105054025B (en) | 2017-11-14 |
Family
ID=54483748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510485578.5A Active CN105054025B (en) | 2015-08-09 | 2015-08-09 | A kind of hypotonic low slag type enteral nutrition powder of low fat for patients with inflammatory bowel disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105054025B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105685973B (en) * | 2016-02-04 | 2018-08-24 | 中山大学附属第六医院 | A kind of Elental |
| CN105795481A (en) * | 2016-03-24 | 2016-07-27 | ***广州总医院 | Special nutritional supplement agent for preoperative patients |
| CN108853085A (en) * | 2017-05-15 | 2018-11-23 | 苏州凯祥生物科技有限公司 | Catechin and epicatechin class compound are used to raise the purposes of MicroRNA-126 expression |
| CN109091410B (en) * | 2017-06-20 | 2021-08-10 | 北京斯利安药业有限公司 | Composition, application thereof, oral preparation and preparation method thereof |
| CN108514119A (en) * | 2018-03-30 | 2018-09-11 | 北京斯利安药业有限公司 | A kind of product of composition, its application and fat-reducing, increasing flesh |
| CN108783459B (en) * | 2018-07-03 | 2022-03-29 | 麦孚营养科技（北京）有限公司 | Pea protein low-residue nutritional formula product, preparation method and application thereof |
| CN114468283B (en) * | 2018-07-03 | 2023-09-15 | 麦孚营养科技（北京）有限公司 | Soybean protein isolate low-residue total nutrient formula product, preparation method and application thereof |
| CN109043505B (en) * | 2018-07-03 | 2022-03-29 | 麦孚营养科技（北京）有限公司 | Marine fish oligopeptide low-residue nutritional formula product, and preparation method and application thereof |
| IT201900003843A1 (en) * | 2019-03-15 | 2020-09-15 | Lo Li Pharma Srl | Treatment of fibroids with vitamin D and an agent such as epigallocatechin gallate (EGCG) |
| CN110463988A (en) * | 2019-07-24 | 2019-11-19 | 浙江禾健生营养科技有限公司 | A kind of full nutrient formulation powder of the hypotonic type of low fat and preparation method thereof |
| CN111419996A (en) * | 2020-06-04 | 2020-07-17 | 青海省人民医院 | Medicine for treating early severe acute pancreatitis |
| CN112841625A (en) * | 2021-01-15 | 2021-05-28 | 首都医科大学附属北京友谊医院 | Nutrient mixture and preparation method thereof |
| CN113303467A (en) * | 2021-05-26 | 2021-08-27 | 青岛大学附属医院 | Enteral nutrition powder suitable for children with abnormal lipid metabolism of 1-10 years old and preparation method thereof |
| CN114099643A (en) * | 2021-11-12 | 2022-03-01 | 费森尤斯卡比华瑞制药有限公司 | Enteral total nutrient emulsion and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007312276B2 (en) * | 2006-10-19 | 2010-06-10 | Société des Produits Nestlé S.A. | Long-term enteral feed for maintenance |
| CN101278736B (en) * | 2008-03-28 | 2014-05-07 | 西安力邦制药有限公司 | Balanced enteral total nutrient preparation suitable for nutrition support of Asian population |
| CN104256595B (en) * | 2014-09-26 | 2016-08-24 | 上海励成营养产品科技股份有限公司 | A kind of many polymerizers of whole protein type enteral nutrition |
-
2015
- 2015-08-09 CN CN201510485578.5A patent/CN105054025B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 表没食子儿茶素没食子酸酯对乙酸诱导的大鼠结肠炎抗炎作用机制的研究;冉志华等;《胃肠病学》;20080825;第13卷(第08期);465-468页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105054025A (en) | 2015-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105054025B (en) | A kind of hypotonic low slag type enteral nutrition powder of low fat for patients with inflammatory bowel disease | |
| EP3806645A1 (en) | Intact pea protein-based nutrient composition | |
| US20210045423A1 (en) | Hydrolyzed Pea Protein-Based Nutrient Composition | |
| JP2012197293A (en) | Total enteral nutritious composition | |
| CN101247735A (en) | Nutrition for obese patients | |
| CN101507494A (en) | Special diet food for patient with hyperlipidemia and hypertension | |
| CN105685973B (en) | A kind of Elental | |
| CN107440088A (en) | Improve operation, the nutrients and preparation method thereof of chemicotherapy tumor patient immunity | |
| CN111990463A (en) | Bovine colostrum composite powder | |
| JPH0394655A (en) | Nutrient feeding composition | |
| KR101456415B1 (en) | The method of manufacturing bar-shaped functional food for diet | |
| CN107467193B (en) | A powder food based on goat milk for special medical use and its preparation method | |
| CN110547472A (en) | peptide-containing formula food with special medical application and preparation method thereof | |
| WO2008140064A1 (en) | Nutrient composition for prevention and amelioration of lifestyle-related disease | |
| CN105533721A (en) | Key fruit oil oral emulsion and preparation method thereof | |
| WO2019106626A1 (en) | Composition for oral administration, the use of the composition in prevention and treatment of mucositis, and a method of treatment of mucositis | |
| JP2022095632A (en) | Cocoa polyphenol and soluble dietary fiber for use in treatment or prevention of disorders associated with above-normal number of granulocytes in tissue | |
| CN110463988A (en) | A kind of full nutrient formulation powder of the hypotonic type of low fat and preparation method thereof | |
| WO2023076572A1 (en) | Nutritional composition for glucose support | |
| CN117137133A (en) | Specific full-nutrition formula food for assisting recovery of tumor patients and preparation method thereof | |
| CN117204567A (en) | Electrolyte supplement and preparation method and application thereof | |
| JP2003516946A (en) | Compositions for improving the proliferative response during gastrointestinal adaptation and use in short bowel syndrome | |
| CN117204572A (en) | Protein supplement and preparation method and application thereof | |
| CN113303467A (en) | Enteral nutrition powder suitable for children with abnormal lipid metabolism of 1-10 years old and preparation method thereof | |
| Lowers | YOUTHFUL SKIN AGING |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |